Evidence has shown that lymphatic drainage contributes to removal of debris from the brain but its role in the accumulation of amyloid β peptides (Aβ) has not been demonstrated. We examined the levels of various forms of Aβ in the brain, plasma and lymph nodes in a transgenic model of Alzheimer's disease (AD) at different ages. Herein, we report on the novel finding that Aβ is present in the cervical and axillary lymph nodes of AD transgenic mice and that Aβ levels in lymph nodes increase over time, mirroring the increase of Aβ levels observed in the brain. Aβ levels in lymph nodes were significantly higher than in plasma. At age 15.5 months, there was a significant increase of monomeric soluble Aβ40 (p = 0.003) and Aβ42 (p = 0.05) in the lymph nodes over the baseline values measured at 6 months of age. In contrast, plasma levels of Aβ40 showed no significant changes (p = 0.68) and plasma levels Aβ42 significantly dropped (p = 0.02) at the same age. Aβ concentration was low to undetectable in splenic lymphoid tissue and several other control tissues including heart, lung, liver, kidneys and intestine of the same animals, strongly suggesting that Aβ peptides in lymph nodes are derived from the brain.
Introduction
Amyloid accumulation in senile plaques is the main neuropathological feature of Alzheimer's disease (AD); however, the mechanisms underlying its age-related accumulation remain elusive. Amyloid fibrils are composed of a 40-42 amino acid peptide called the amyloid beta protein (Aβ) (Glenner and Wong, 1984; Masters et al., 1985) . Inadequate clearance of Aβ from the brain is considered to play an important role in amyloid accumulation (Neve and Robakis, 1998; Sambamurti et al., 2011) . Prior research has demonstrated that peripheral lymph nodes participate in immune-surveillance and antigen presentation in the brain, particularly during neuro-inflammatory processes (Cserr et al., 1992; Hatterer et al., 2008) ; however, there is negligible information as to the potential participation of this system on Aβ clearance. Although the brain lacks lymphatic channels, circulation of cerebrospinal fluid (CSF) and immune-competent cells such as dendritic and perivascular cells between brain (mainly perivascular spaces) and peripheral lymph nodes have been demonstrated (Boulton et al., 1996; Bradbury et al., 1981; Brinker et al., 1997; Cserr et al., 1992; Hatterer et al., 2008; Koh et al., 2005; Vega and Jonakait, 2004; Weller et al., 1998) . It has been suggested that Aβ is present in the "interstitial cerebral fluid" (ICF) and that it might be drained into lymph nodes (Nedergaard, 2013; Weller et al., 1998) . The route by which lymphatic drainage of Aβ may occur was suggested to be along basement membranes of cerebral capillaries and arteries (Carare et al., 2013; Hawkes et al., 2011) . However, actual demonstration of Aβ in the lymph nodes has never, to our knowledge, been shown prior to our study. This may have been in part due to the arduous micro-dissection methods involved and to nuances of sample preparation for Aβ quantification.
For this investigation, we used a highly sensitive sandwich ELISA methodology (Asami-Odaka et al., 1995; Matsubara et al., 1999; Suzuki et al., 1994) with various Aβ antibodies to test the hypothesis that Aβ is present in the lymph nodes and to relate its levels to those measured in the plasma and brain at different ages.
Methods

AD transgenic mice
We used Tg2576 transgenic mice. These mice express the 695-amino-acid isoform of human AβPP containing the double Lys670 ➔ 
